{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:41:01Z","timestamp":1786736461583,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Family Med Prim Care"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jfmpc.jfmpc_943_19","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T02:43:36Z","timestamp":1583117016000},"page":"531","source":"Crossref","is-referenced-by-count":15,"title":["Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection\u2014A brief review of literature"],"prefix":"10.4103","volume":"9","author":[{"given":"Ekta","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2249-4863.279360-1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1601-0825.2007.01419.x","article-title":"Hepatitis C: A clinical review","author":"Modi","year":"2008","journal-title":"Oral Dis"},{"key":"key-10.4103\/2249-4863.279360-2","first-page":"838","article-title":"Inhibitors of the HCV NS5B polymerase: New hope for the treatment of hepatitis C infections","author":"Beaulieu","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"key-10.4103\/2249-4863.279360-3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1743-422X-8-161","article-title":"An overview of HCV molecular biology, replication and immune responses","author":"Ashfaq","year":"2011","journal-title":"Virol J"},{"key":"key-10.4103\/2249-4863.279360-4","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.1073\/pnas.91.17.8239","article-title":"Sequence analysis of the core gene of 14 hepatitis C virus genotypes","author":"Bukh","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2249-4863.279360-5","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1128\/jvi.68.6.3631-3641.1994","article-title":"Biosynthesis and biochemical properties of the hepatitis C virus core protein","author":"Santolini","year":"1994","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-6","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1074\/jbc.M108798200","article-title":"The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins","author":"Hope","year":"2002","journal-title":"J Biol Chem"},{"key":"key-10.4103\/2249-4863.279360-7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/gast.2002.31001","article-title":"Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus","author":"Lerat","year":"2002","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2249-4863.279360-8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1369-5274(02)00341-7","article-title":"Interaction between hepatitis C virus proteins and host cell factors","author":"Tellinghuisen","year":"2002","journal-title":"Curr Opin Microbiol"},{"key":"key-10.4103\/2249-4863.279360-9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0014-5793(03)00635-5","article-title":"Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins","author":"Drummer","year":"2003","journal-title":"FEBS Lett"},{"key":"key-10.4103\/2249-4863.279360-10","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1128\/JVI.79.13.8400-8409.2005","article-title":"Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins","author":"Goffard","year":"2005","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0014-5793(02)03851-6","article-title":"The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine","author":"Griffin","year":"2003","journal-title":"FEBS Lett"},{"key":"key-10.4103\/2249-4863.279360-12","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1371\/journal.ppat.0030103","article-title":"Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions","author":"Steinmann","year":"2007","journal-title":"PLoS Pathog"},{"key":"key-10.4103\/2249-4863.279360-13","doi-asserted-by":"crossref","unstructured":"Khromykh AA, Westaway EG. Subgenomic replicons of the flavivirus Kunjin: Construction and applications. J Virol 1997;71:1497-505.","DOI":"10.1128\/jvi.71.2.1497-1505.1997"},{"key":"key-10.4103\/2249-4863.279360-14","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","author":"Pietschmann","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.4103\/2249-4863.279360-15","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/JVI.72.8.6758-6769.1998","article-title":"Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus","author":"Gallinari","year":"1998","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-16","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.74.5.2293-2304.2000","article-title":"Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines","author":"Wolk","year":"2000","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1128\/jvi.71.1.790-796.1997","article-title":"The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation","author":"Asabe","year":"1997","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-18","doi-asserted-by":"crossref","unstructured":"Lin C, Wu JW, Hsiao K, Su MS. The hepatitis C virus NS4A protein: Interactions with the NS4B and NS5A proteins. J Virol 1997;71:6465-71.","DOI":"10.1128\/jvi.71.9.6465-6471.1997"},{"key":"key-10.4103\/2249-4863.279360-19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/viro.2001.0873","article-title":"The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein","author":"Hugle","year":"2001","journal-title":"Virology"},{"key":"key-10.4103\/2249-4863.279360-20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1099\/vir.0.19691-0","article-title":"The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity","author":"Macdonald","year":"2004","journal-title":"J Gen Virol"},{"key":"key-10.4103\/2249-4863.279360-21","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1128\/jvi.71.10.7187-7197.1997","article-title":"Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: Properties of the NS5A-associated kinase","author":"Reed","year":"1997","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/j.1460-2075.1996.tb00329.x","article-title":"Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus","author":"Behrens","year":"1996","journal-title":"Embo J"},{"key":"key-10.4103\/2249-4863.279360-23","first-page":"S21","article-title":"Course and outcome of hepatitis C","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"key-10.4103\/2249-4863.279360-24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"key-10.4103\/2249-4863.279360-25","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: Incidence and risk factors","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2249-4863.279360-26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/2249-4863.279360-27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"key-10.4103\/2249-4863.279360-28","first-page":"20","article-title":"Global burden of disease (GBD) for hepatitis C","author":"Global","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/2249-4863.279360-29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key-10.4103\/2249-4863.279360-30","unstructured":"Hepatitis C--global prevalence (update) Wkly Epidemiol Rec 1999;74:425-7."},{"key":"key-10.4103\/2249-4863.279360-31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jmv.20343","article-title":"Hepatitis C virus infection in cameroon: A cohort-effect","author":"Nerrienet","year":"2005","journal-title":"J Med Virol"},{"key":"key-10.4103\/2249-4863.279360-32","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","article-title":"HCV burden of infection in Egypt: Results from a nationwide survey","author":"Guerra","year":"2012","journal-title":"J Viral Hepat"},{"key":"key-10.4103\/2249-4863.279360-33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12038-008-0065-0","article-title":"Hepatitis C in India","author":"Mukhopadhyaya","year":"2008","journal-title":"J Biosci"},{"key":"key-10.4103\/2249-4863.279360-34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"key-10.4103\/2249-4863.279360-35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0065-3527(08)00002-X","article-title":"Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems","author":"Gottwein","year":"2008","journal-title":"Adv Virus Res"},{"key":"key-10.4103\/2249-4863.279360-36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/2249-4863.279360-37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2008.02.001","article-title":"Changing HCV genotypes distribution in Poland--relation to source and time of infection","author":"Chlabicz","year":"2008","journal-title":"J Clin Virol"},{"key":"key-10.4103\/2249-4863.279360-38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jmv.20828","article-title":"Genetic characterization of hepatitis C virus strains in Estonia: Fluctuations in the predominating subtype with time","author":"Tallo","year":"2007","journal-title":"J Med Virol"},{"key":"key-10.4103\/2249-4863.279360-39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2893.2005.00649.x","article-title":"Molecular epidemiology of hepatitis C virus (HCV) in Greece: Temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates","author":"Katsoulidou","year":"2006","journal-title":"J Viral Hepat"},{"key":"key-10.4103\/2249-4863.279360-40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","article-title":"Asystematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","author":"Sievert","year":"2011","journal-title":"Liver Int"},{"key":"key-10.4103\/2249-4863.279360-41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2011.04714.x","article-title":"Systematic review: Epidemiology of hepatitis C genotype 6 and its management","author":"Chao","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/2249-4863.279360-42","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1542-3565(05)00711-1","article-title":"Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6","author":"Nguyen","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/2249-4863.279360-43","first-page":"441","article-title":"Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany","author":"Mauss","year":"2012","journal-title":"Z Gastroenterol"},{"key":"key-10.4103\/2249-4863.279360-44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10408410903357455","article-title":"An overview about hepatitis C: A devastating virus","author":"Bostan","year":"2010","journal-title":"Crit Rev Microbiol"},{"key":"key-10.4103\/2249-4863.279360-45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4254\/wjh.v5.i9.496","article-title":"Hepatitis C genotype 6: A concise review and response-guided therapy proposal","author":"Bunchorntavakul","year":"2013","journal-title":"World J Hepatol"},{"key":"key-10.4103\/2249-4863.279360-46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"Asystematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","author":"Cornberg","year":"2011","journal-title":"Liver Int"},{"key":"key-10.4103\/2249-4863.279360-47","unstructured":"Porter L. Hepatitis C: The Evolution of Treatment [Internet]. Lucinda Porter, RN header image. 2015 [cited 2018 Jun 25]. Available from: http:\/\/www.lucindaporterrn.com\/hepatitis-c-the-evolution-of-treatment\/."},{"key":"key-10.4103\/2249-4863.279360-48","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"key-10.4103\/2249-4863.279360-49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2012.01590.x","article-title":"A practical guide for the use of Boceprevir and Telaprevir for the treatment of hepatitis C","author":"Jacobson","year":"2012","journal-title":"J Viral Hepatitis"},{"key":"key-10.4103\/2249-4863.279360-50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1473-3099(13)70074-4","article-title":"Sofosbuvir: The final nail in the coffin for hepatitis C","author":"Manns","year":"2013","journal-title":"Lancet Infectious Diseases"},{"key":"key-10.4103\/2249-4863.279360-51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","article-title":"Treating hepatitis C: Current standard of care and emerging direct-acting antiviral agents","author":"Poordad","year":"2012","journal-title":"J Viral Hepat"},{"key":"key-10.4103\/2249-4863.279360-52","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"key-10.4103\/2249-4863.279360-53","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti-hepatitis C virus drugs in development","author":"Schaefer","year":"2012","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2249-4863.279360-54","unstructured":"Pockros PJ. Direct-acting antivirals for the treatment of hepatitis C virus infection. [Last accessed on 2018 Jun 25]. UpToDate."},{"key":"key-10.4103\/2249-4863.279360-55","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1128\/JVI.73.8.6490-6499.1999","article-title":"Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving \u03b1 interferon therapy","author":"Pawlotsky","year":"1999","journal-title":"J Virol"},{"key":"key-10.4103\/2249-4863.279360-56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamicsin vivo and the antiviral efficacy of interferon-\u03b1 therapy","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"key-10.4103\/2249-4863.279360-57","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrgastro.2009.102","article-title":"Hepatitis: HCV variability, the immune system and resistance to antiviral drugs","author":"Pawlotsky","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.4103\/2249-4863.279360-58","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"key-10.4103\/2249-4863.279360-59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bpg.2012.09.011","article-title":"The role of resistance in HCV treatment","author":"Vermehren","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key-10.4103\/2249-4863.279360-60","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","author":"Kati","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2249-4863.279360-61","unstructured":"Hcvguidelines.org. (2018). HCV Resistance Primer | HCV Guidance. [online]. Available from: https:\/\/www.hcvguidelines.org\/evaluate\/resistance. [Last accessed 2018 Jun 29]."},{"key":"key-10.4103\/2249-4863.279360-62","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/2249-4863.279360-63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","author":"Wyles","year":"2018","journal-title":"Antivir Ther"},{"key":"key-10.4103\/2249-4863.279360-64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2249-4863.279360-65","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","article-title":"A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments?","author":"Radley","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"key-10.4103\/2249-4863.279360-66","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13063-018-2768-3","article-title":"Community-based provision of direct-acting antiviral therapy for hepatitis C: Study protocol and challenges of a randomized controlled trial","author":"Wade","year":"2018","journal-title":"Trials"},{"key":"key-10.4103\/2249-4863.279360-67","unstructured":"[Internet]. Mohfw.gov.in. 2019 [cited 2019 Nov 20]. Available from: https:\/\/mohfw.gov.in\/sites\/default\/files\/National%20Action%20Plan_Lowress_Reference%20file.pdf."}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:42:09Z","timestamp":1786732929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_943_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["279360"],"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_943_19","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}